November 29, 2016 - By Hazel Jackson
Professional analysts at Aegis Capital has initiated coverage on Revance Therapeutics (NASDAQ:RVNC) with a “Buy” rating. The PT for RVNC is $28. It means a potential upside of 58.19% from firm’s last stock price.
Out of 4 analysts covering Revance Therapeutics (NASDAQ:RVNC), 3 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 75% are positive. $46 is the highest target while $22 is the lowest. The $34 average target is 92.09% above today’s ($17.7) stock price. Revance Therapeutics has been the topic of 5 analyst reports since August 22, 2015 according to StockzIntelligence Inc. The rating was downgraded by Brean Capital to “Hold” on Tuesday, June 14. The rating was downgraded by Zacks to “Hold” on Saturday, August 22. The stock has “Buy” rating given by SunTrust on Wednesday, March 23. Suntrust Robinson maintained Revance Therapeutics Inc (NASDAQ:RVNC) on Tuesday, June 14 with “Buy” rating. As per Monday, November 23, the company rating was initiated by Guggenheim.
About 41,202 shares traded hands. Revance Therapeutics Inc (NASDAQ:RVNC) has declined 10.61% since April 26, 2016 and is downtrending. It has underperformed by 15.87% the S&P500.
Analysts await Revance Therapeutics Inc (NASDAQ:RVNC) to report earnings on March, 1. They expect $-0.88 EPS, down 6.02% or $0.05 from last year’s $-0.83 per share. After $-0.64 actual EPS reported by Revance Therapeutics Inc for the previous quarter, Wall Street now forecasts 37.50% negative EPS growth.
Insitutional Activity: The institutional sentiment decreased to 0.89 in Q2 2016. Its down 0.50, from 1.39 in 2016Q1. The ratio fall, as 15 funds sold all Revance Therapeutics Inc shares owned while 16 reduced positions. 9 funds bought stakes while 34 increased positions. They now own 28.60 million shares or 5.50% more from 27.11 million shares in 2016Q1.
Tiaa Cref Invest Management owns 61,589 shares or 0% of their US portfolio. Rhumbline Advisers last reported 0% of its portfolio in the stock. The New York-based Lombard Odier Asset (Usa) has invested 0.04% in Revance Therapeutics Inc (NASDAQ:RVNC). Essex Woodlands Health Ventures Inc last reported 15.74% of its portfolio in the stock. Blackrock owns 1,893 shares or 0% of their US portfolio. Moreover, Manufacturers Life Insur The has 0% invested in Revance Therapeutics Inc (NASDAQ:RVNC) for 14,920 shares. Blackrock Institutional Trust Com Na has 514,939 shares for 0% of their US portfolio. Morgan Stanley owns 90,037 shares or 0% of their US portfolio. The Illinois-based Gru One Trading Ltd Partnership has invested 0% in Revance Therapeutics Inc (NASDAQ:RVNC). Moreover, Tower Rech Cap Limited Com (Trc) has 0% invested in Revance Therapeutics Inc (NASDAQ:RVNC) for 191 shares. Legal General Gru Plc holds 0% or 3,561 shares in its portfolio. Great Point Prns Lc holds 0.08% or 21,665 shares in its portfolio. Aqr Mgmt Limited Company holds 12,073 shares or 0% of its portfolio. Rhenman & Asset Mgmt has invested 0.53% of its portfolio in Revance Therapeutics Inc (NASDAQ:RVNC). Deutsche Retail Bank Ag has 0% invested in the company for 22,184 shares.
Insider Transactions: Since June 13, 2016, the stock had 0 buys, and 3 selling transactions for $411,454 net activity. $18,250 worth of Revance Therapeutics Inc (NASDAQ:RVNC) was sold by Ruegg Curtis on Monday, June 13. Browne L Daniel also sold $178,199 worth of Revance Therapeutics Inc (NASDAQ:RVNC) on Wednesday, October 26.
Revance Therapeutics, Inc. is a biotechnology company. The company has a market cap of $493.50 million. The Firm is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. It currently has negative earnings. The Company’s TransMTS technology enables delivery of botulinum toxin type A through investigational drug product candidates, including DaxibotulinumtoxinA Topical Gel , or RT001 topical, and DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable.
According to Zacks Investment Research, “Revance is a Silicon Valley-based biotechnology company. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance’s science is based upon a proprietary TransMTSÂ® peptide technology, which when combined with active drug molecules, may help address current unmet needs. Revance’s initial focus is on developing daxibotulinumtoxinA, the company’s highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company’s lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines and cervical dystonia and has the potential to be the first long-acting neurotoxin. The company holds worldwide rights for all indications of RT002 injectable and RT001 topical and the pharmaceutical uses of the TransMTS technology platform.”
Revance Therapeutics, Inc., incorporated on August 10, 1999, is a biotechnology company. The Firm is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. The Company’s TransMTS technology enables delivery of botulinum toxin type A through approximately two investigational drug product candidates, DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical, and DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable. The Company’s botulinum toxin-peptide complex has over two components that contribute to the performance of RT001 and RT002. First, its TransMTS peptide provides the delivery across the skin and restricts the toxin molecule to the target site. Second, the botulinum toxin type A provides the mechanism of pharmacologic action and is responsible for the drug effects demonstrated in its clinical trials.
Another recent and important Revance Therapeutics Inc (NASDAQ:RVNC) news was published by Fool.com which published an article titled: “Why Revance Therapeutics Is Crashing 23% Today” on June 14, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.